Corton Capital’s Ginkgo Bioworks DNA Stock Holding History

Corton Capital’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,968	Closed	-$157K	–	256
2025 Q2	$157K	Buy	+13,968	New	+$108K	0.18%	274

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Corton Capital's DNA Position: Q3 2025 in Review

Corton Capital sold out of Ginkgo Bioworks (DNA) in Q3 2025, closing a stake of 13,968 shares — an estimated $157K sold.

Corton Capital first reported a position in DNA in Q2 2025 and held it in 1 quarter. The position peaked at $157K in Q2 2025. 173 funds tracked by Wall St. Rank hold DNA as of Q3 2025.

Corton Capital reported no remaining Ginkgo Bioworks position as of Q3 2025 after selling out during the quarter.
Corton Capital sold 13,968 Ginkgo Bioworks shares in Q3 2025, an estimated $157K.
Corton Capital first reported a position in Ginkgo Bioworks in Q2 2025 and held it in 1 quarter.
Corton Capital's Ginkgo Bioworks position peaked at $157K in Q2 2025.
173 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2025.

Based on Corton Capital's 13F filing for Q3 2025, filed 14 Nov 2025.